MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Puma Biotechnology Inc

Fermé

SecteurSoins de santé

5.23 0.58

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.13

Max

5.28

Chiffres clés

By Trading Economics

Revenu

2.9M

5.9M

Ventes

6.4M

52M

P/E

Moyenne du Secteur

5.081

37.257

Marge bénéficiaire

11.166

Employés

172

EBITDA

6.8M

11M

Recommandations

By TipRanks

Recommandations

Vente

Prévisions sur 12 Mois

-42.08% downside

Dividendes

By Dow Jones

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

100M

258M

Ouverture précédente

4.65

Clôture précédente

5.23

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Puma Biotechnology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 oct. 2025, 20:45 UTC

Résultats

Costco Wholesale Sales Climb in September, Early October

8 oct. 2025, 20:12 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 oct. 2025, 16:39 UTC

Principaux Mouvements du Marché

Mining Shares Rise as Gold Prices Soar

8 oct. 2025, 23:45 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8 oct. 2025, 23:43 UTC

Market Talk

Gold Falls on Possible Profit-Taking -- Market Talk

8 oct. 2025, 23:18 UTC

Acquisitions, Fusions, Rachats

JD Logistics to Finance Acquisition Using Internal Funds

8 oct. 2025, 23:17 UTC

Acquisitions, Fusions, Rachats

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 oct. 2025, 23:16 UTC

Acquisitions, Fusions, Rachats

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 oct. 2025, 21:54 UTC

Market Talk
Résultats

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 oct. 2025, 21:30 UTC

Market Talk

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 oct. 2025, 21:26 UTC

Market Talk
Résultats

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 oct. 2025, 19:15 UTC

Market Talk

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 oct. 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 oct. 2025, 18:47 UTC

Market Talk

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

TaskUs Will Remain a Publicly Traded Co >TASK

8 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 oct. 2025, 18:45 UTC

Acquisitions, Fusions, Rachats

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 oct. 2025, 18:07 UTC

Market Talk

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 oct. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Energy & Utilities Roundup: Market Talk

8 oct. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 oct. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 oct. 2025, 15:57 UTC

Market Talk

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 oct. 2025, 15:56 UTC

Market Talk

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 oct. 2025, 15:53 UTC

Market Talk

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 oct. 2025, 15:44 UTC

Acquisitions, Fusions, Rachats

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 oct. 2025, 15:44 UTC

Acquisitions, Fusions, Rachats

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 oct. 2025, 15:43 UTC

Acquisitions, Fusions, Rachats

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 oct. 2025, 15:42 UTC

Acquisitions, Fusions, Rachats

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Comparaison

Variation de prix

Puma Biotechnology Inc prévision

Objectif de Prix

By TipRanks

-42.08% baisse

Prévisions sur 12 Mois

Moyen 3 USD  -42.08%

Haut 4 USD

Bas 2 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Vente

2 ratings

0

Achat

1

Maintien

1

Vente

Score Technique

By Trading Central

3.07 / 3.075Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat